Vaxxas has obtained an exclusive license to the SARS-CoV-2 spike subunit vaccine, HexaPro, from The University of Texas at Austin (UT Austin), in the US, for inoculation using a patch.

Together with a companion background technology licence granted by the US National Institutes of Health (NIH), the licence from UT Austin will help Vaxxas to develop a needle-free, room-temperature stable Covid-19 vaccine patch, which will enter clinical trials.

A stabilised protein, HexaPro can imitate the structure of the spike protein present on the coronavirus surface to prepare the human immune system to detect and destroy the SARS-CoV-2 virus.

It is the first needle-free Covid-19 vaccine to be delivered using the company’s high-density microarray patch (HD-MAP) technology.

Compared to the spikes used in various Covid-19 vaccines marketed in the US, HexaPro has spike proteins that have been altered to be highly stable and immunogenic.

The company intends to conclude the Phase I clinical trial of its HexaPro/HD-MAP Covid-19 vaccine this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to preclinical data, the vaccine delivered using the HD-MAP technology of Vaxxas provided improved virus neutralising antibody and T-cell responses against all variants of concern of the virus, including delta and omicron, versus needle and syringe administration of HexaPro.

Vaxxas president and CEO David Hoey said: “The current pandemic has underscored the lifesaving potential of innovative technologies, and we think novel vaccination approaches clearly offer unique benefits. 

“Vaxxas’ proprietary HD-MAP technology can enable cost-effective distribution without the need for extensive refrigeration, and our easy-to-use device offers the potential for self-administration. 

“These attributes offer a truly scalable, distinct and differentiated approach to greatly improve pandemic vaccination capabilities globally.”

The HD-MAP patch is created to eradicate the requirements for refrigerated supply and permits administration by people with minimal training.